Silencing of FABP 1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
| Autor: | Tatsuya Kusudo, Hitoshi Yamashita, Miki Egawa, Tamaki Takeuchi, Takako Mukai |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cirrhosis medicine.disease_cause General Biochemistry Genetics and Molecular Biology Lipid peroxidation 03 medical and health sciences chemistry.chemical_compound NAFLD Internal medicine Nonalcoholic fatty liver disease medicine Research Articles Triglyceride business.industry Lipid metabolism medicine.disease digestive system diseases 030104 developmental biology Endocrinology Biochemistry chemistry Hepatocellular carcinoma FABP1 Steatosis business Oxidative stress Research Article |
| Zdroj: | FEBS Open Bio |
| ISSN: | 2211-5463 |
| DOI: | 10.1002/2211-5463.12240 |
| Popis: | Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide and has been identified as a risk factor for cirrhosis and hepatocellular carcinoma. However, there is no effective pharmacologic treatment for NAFLD. FABP1 is a liver‐specific fatty acid‐binding protein (FABP) that plays important roles in intracellular lipid metabolism in the liver. We investigated the effect of repression of FABP1 expression on NAFLD, using adenovirus‐mediated silencing of FABP1. FABP1 knockdown in the liver decreased the liver weight and hepatic triglyceride (TG) accumulation. The expression of inflammatory and oxidative stress markers in the liver was also reduced. The level of thiobarbituric acid‐reactive substances, a marker of lipid peroxidation, in the liver of FABP1 knockdown mice was significantly decreased. These results suggest that FABP1 reduction in the liver is an effective approach against NAFLD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text